Orally Inhaled Corticosteroids to 2022

Chart_Collage_160  Published April 2015  •  Catalog no. RHC297X  •  Price US $2,850

Asthma continues to be a health segment that presents challenges to the caregiver community. Patient adherence with prescribing instructions and treatment protocols remains sub-optimal across all patient categories, but particularly for the young and the elderly. This has led to significant interest on the part of device and combination product providers directed toward the development easier-to-use inhalers. Because they reduce inflammation and swelling in the airways, orally inhaled corticosteroids are an indispensable tool for the treatment of asthma. The market entry of combination drug inhalers that deliver a corticosteroid and a bronchodilator from the same inhaler are providing important options for both clinicians and patients.

Bar_Graph Orally Inhaled Corticosteroids to 2022 Report Prospectus (Download PDF)

Blue document Orally Inhaled Corticosteroids to 2022 Report Order Form (Download PDF)


• Analyzes the market for corticosteroid drugs delivered via oral inhalers
• Assesses inhalation device technology for delivering corticosteroids orally, and evaluates product technology issues and evolving market factors
• Provides detailed assessments of orally inhaled corticosteroid product segments, growth prospects and market potential
• Provides market data and forecasts for orally inhaled corticosteroid drugs to 2022
• Profiles inhaled drug product market participants, their technology, product development activity, and business strategies
• Evaluates the impact of economic, technology, and regulatory factors on inhaled drug companies and their alliance partners

Summary of Contents

Executive Summary

Orally Inhaled Corticosteroid Market Overview

The Asthma Therapeutics Marketspace
Competing Drug Treatments
Corticosteroids and Asthma
Demand Drivers
Technology Factors
Competitive Landscape

Asthma Market Risks and Opportunities

Global Patient Demographics
Regional Market Drivers
Pediatric Asthma –the Growing Therapeutic Need

Inhaler Technologies for Delivering Corticosteroids

Dry Powder Inhalers
DPI Formulation Technology
Characteristics and Parameters
DPI Excipients and Packaging
Metered Dose Inhalers
MDI Device Selection Criteria
Ease-of-Use Factors

Inhaled Corticosteroids – Product Analysis, Market Data & Forecasts

Beclomethasone, QVAR 40/80 (MDI)
Budesonide, Pulmicort (DPI)
Budesonide, Pulmicort (Nebulizer)
Generic Budesonide (Nebulizer)
Budesonide/Formoterol (Symbicort) Combination Drug Inhaler (MDI)
Ciclesonide, Alvesco (MDI)
Ciclesonide, Zetonna (MDI)
Flunisolide, Aerospan HFA (MDI)
Fluticasone, Arnuity Ellipta (DPI)
Fluticasone, Flovent HFA (MDI)
Fluticasone, Flovent Diskus50/100/250 (DPI)
Fluticasone/Salmeterol (Advair HFA) Combination Drug Inhaler (MDI)
Fluticasone/Salmeterol (Advair Diskus) Combination Drug Inhaler (DPI)
Fluticasone/Vilanterol (Breo Ellipta) Combination Drug Inhaler (DPI)
Mometasone, Asmanex HFA (MDI)
Mometasone, Asmanex Twisthaler (DPI)
Umeclidinium, Incruse Ellipta (DPI)
Umeclidinium/Vilanterol (Anora Ellipta) Combination Drug Inhaler (DPI)

Market Factors

Regulatory Issues
Patient Compliance
Prescribing Trends
Healthcare Economics
Regional Market Factors
Connected Devices

Market Sector Company Profiles